Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

ZymoGenetics23 enrolled

Overview

The purpose of the study is to evaluate whether recombinant IL-21 used in combination with rituximab is safe for patients with non-Hodgkin's lymphoma (NHL).

This is a Phase 1 open-label dose-escalation study of rituximab + rIL-21 combination therapy, administered once weekly for 4 weeks following an initial treatment with one dose of rituximab alone to patients with B-cell non-Hodgkin's lymphoma (NHL) who have failed prior therapy(ies). A standard dose of rituximab will be used. Increasing doses of rIL-21 will be studied sequentially in different groups of patients, starting with 30 μg/kg. Before starting treatment with rituximab + rIL-21, patients will be treated with one dose of rituximab alone to look for rituximab infusion-related symptoms (such as fever, chills, and rigors). Patients who have severe infusion-related side effects after the first dose of rituximab will not go on to receive IL-21. Those who do not have unacceptable rituximab-related side effects will receive intravenous rIL-21 at least 60 minutes after completing the rituximab infusion at the rest of the weekly dosing visits. Patients will be evaluated for safety over the course of the study. Disease evaluation (tumor restaging) will be performed 2 weeks following completion of the first 4-week treatment cycle. Patients with stable disease or better at this evaluation may go on to receive a second 4-week treatment cycle of rituximab + rIL-21. Patients may be in the study for 2 to 4 months.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin

Interventions

recombinant human interleukin 21 and rituximabDRUG

rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of CD20+ B-cell NHL * Disease measurable by computed tomography (CT) scan * Has failed at least one prior systemic therapy for NHL * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate hepatic and renal function * Adequate bone marrow function Exclusion Criteria: * Presence of acute infection or other significant systemic illness * White blood cell (WBC) count \> 50,000/mm3 in peripheral blood * Central nervous system involvement by malignancy * Previous allogenic transplant or autotransplant within 6 months of enrollment * Other current malignancy or known history of cancer within 5 years * Received systemic corticosteroids, chemotherapy, immunotherapy, biologic therapy, antibody therapy (e.g., rituximab), radiation therapy, and/or investigational agent(s) within 1 month of enrollment

Locations (1)

University of California, Los Angeles

Los Angeles, California, United States

Outcomes

Primary Outcomes

Incidence and severity of adverse events through 1 month after completing treatment

Time frame: During treatment and through 1 month after completing treatment

Incidence and grade of clinical laboratory abnormalities through 1 month after treatment

Time frame: During treatment and through 1 month after completing treatment

Secondary Outcomes

Disease response by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas 2 weeks after completion of the first treatment cycle

Time frame: Two and four weeks after completion of the first and second cycles, respectively

Immunogenicity by incidence of anti-rIL-21 antibodies up to 1 month after treatment

Time frame: During treatment and up to 1 month after completing treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.